Ligand Pharmaceuticals
LGND
251 hedge funds and large institutions have $2.71B invested in Ligand Pharmaceuticals in 2016 Q1 according to their latest regulatory filings, with 42 funds opening new positions, 113 increasing their positions, 71 reducing their positions, and 22 closing their positions.
91% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 22
59% more repeat investments, than reductions
Existing positions increased: 113 | Existing positions reduced: 71
33% more funds holding in top 10
Funds holding in top 10: 9 → 12 (+3)
8% more capital invested
Capital invested by funds: $2.51B → $2.71B (+$197M)
8% more funds holding
Funds holding: 233 → 251 (+18)
58% less call options, than puts
Call options by funds: $3.61M | Put options by funds: $8.65M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
1832 Asset Management
Toronto,
Ontario, Canada
|
+$45.8M |
| 2 |
AL
AJO LP
Philadelphia,
Pennsylvania
|
+$40.1M |
| 3 |
Wells Fargo
San Francisco,
California
|
+$28.2M |
| 4 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
+$15.8M |
| 5 |
CWAM
Columbia Wanger Asset Management
Chicago,
Illinois
|
+$15.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dimensional Fund Advisors
Austin,
Texas
|
-$18M |
| 2 |
RIM
RS Investment Management
San Francisco,
California
|
-$17.3M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$16.4M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$13.2M |
| 5 |
Renaissance Technologies
New York
|
-$5.6M |
LGND Hedge Fund Activity: Q1 2016 in Review
251 of the 3,754 institutional investors tracked by Wall St. Rank reported a position in Ligand Pharmaceuticals (LGND) for Q1 2016, worth a combined $2.71B — up 7.8% from $2.51B a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new LGND positions and 22 closed out — a net gain of 20 holders — while 113 added to existing stakes and 71 trimmed.
The largest buyer was 1832 Asset Management, opening a new position worth an estimated $45.8M. The largest seller was Dimensional Fund Advisors, cutting an estimated $18M.
- 251 institutional investors held Ligand Pharmaceuticals (LGND) as of Q1 2016, up from 233 in Q4 2015.
- Funds reported $2.71B of Ligand Pharmaceuticals stock for Q1 2016, up 7.8% quarter-over-quarter.
- 42 funds opened new Ligand Pharmaceuticals positions in Q1 2016 and 22 closed out, a net change of +20 holders.
- The largest Ligand Pharmaceuticals buyer in Q1 2016 was 1832 Asset Management, an estimated $45.8M added.
- The largest Ligand Pharmaceuticals seller in Q1 2016 was Dimensional Fund Advisors, an estimated $18M sold.
Based on aggregated 13F filings for Q1 2016.